These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 30880459)
21. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis. Moreno MJ; Gallardo A; Novelli S; Mozos A; Aragó M; Pavón MÁ; Céspedes MV; Pallarès V; Falgàs A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I PLoS One; 2018; 13(6):e0198789. PubMed ID: 29920526 [TBL] [Abstract][Full Text] [Related]
22. Highly Tumorigenic Diffuse Large B Cell Lymphoma Cells Are Produced by Coculture with Stromal Cells. Lin Z; Chen B; Wu T; Xu X Acta Haematol; 2018; 139(4):201-216. PubMed ID: 29791894 [TBL] [Abstract][Full Text] [Related]
23. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511 [TBL] [Abstract][Full Text] [Related]
24. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. Xu PP; Sun YF; Fang Y; Song Q; Yan ZX; Chen Y; Jiang XF; Fei XC; Zhao Y; Leboeuf C; Li B; Wang CF; Janin A; Wang L; Zhao WL Sci Rep; 2017 Aug; 7(1):7433. PubMed ID: 28785100 [TBL] [Abstract][Full Text] [Related]
25. Targeting chemokines for acute lymphoblastic leukemia therapy. Hong Z; Wei Z; Xie T; Fu L; Sun J; Zhou F; Jamal M; Zhang Q; Shao L J Hematol Oncol; 2021 Mar; 14(1):48. PubMed ID: 33743810 [TBL] [Abstract][Full Text] [Related]
26. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma. Ji H; Niu X; Yin L; Wang Y; Huang L; Xuan Q; Li L; Zhang H; Li J; Yang Y; An W; Zhang Q Cell Physiol Biochem; 2018; 45(3):951-961. PubMed ID: 29428948 [TBL] [Abstract][Full Text] [Related]
27. Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling. Nie M; Yang L; Bi X; Wang Y; Sun P; Yang H; Liu P; Li Z; Xia Y; Jiang W Clin Cancer Res; 2019 Mar; 25(6):1867-1879. PubMed ID: 30446590 [TBL] [Abstract][Full Text] [Related]
28. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. Moreno MJ; Bosch R; Dieguez-Gonzalez R; Novelli S; Mozos A; Gallardo A; Pavón MÁ; Céspedes MV; Grañena A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I J Pathol; 2015 Feb; 235(3):445-55. PubMed ID: 25231113 [TBL] [Abstract][Full Text] [Related]
29. Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma. Li X; Liu M; Shi Q; Fang Y; Fu D; Shen ZX; Yi H; Wang L; Zhao W Hematol Oncol; 2023 Apr; 41(2):230-238. PubMed ID: 35304777 [TBL] [Abstract][Full Text] [Related]
30. Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL). Zhang W; Fan Y; Li M; Yang L; Zhang Z; Liu L Dis Markers; 2021; 2021():4894022. PubMed ID: 34567285 [TBL] [Abstract][Full Text] [Related]
31. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab. Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962 [TBL] [Abstract][Full Text] [Related]
32. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma. Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619 [TBL] [Abstract][Full Text] [Related]
33. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268 [TBL] [Abstract][Full Text] [Related]
34. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma]. Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230 [TBL] [Abstract][Full Text] [Related]
35. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas. Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887 [TBL] [Abstract][Full Text] [Related]
36. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity]. Miyazaki K Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444 [TBL] [Abstract][Full Text] [Related]
37. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma. Higashi M; Tokuhira M; Fujino S; Yamashita T; Abe K; Arai E; Kizaki M; Tamaru J Leuk Lymphoma; 2016; 57(1):161-6. PubMed ID: 25860238 [TBL] [Abstract][Full Text] [Related]
38. Chemokines, chemokine receptors, and cancer metastasis. Kakinuma T; Hwang ST J Leukoc Biol; 2006 Apr; 79(4):639-51. PubMed ID: 16478915 [TBL] [Abstract][Full Text] [Related]
39. Treatment of Diffuse Large B-Cell Lymphoma. Miyazaki K J Clin Exp Hematop; 2016; 56(2):79-88. PubMed ID: 27980306 [TBL] [Abstract][Full Text] [Related]
40. Chemokines and Their Receptors: Predictors of Therapeutic Potential in Tumor Microenvironment on Esophageal Cancer. Huang CG; Liu Q; Zheng ST; Liu T; Tan YY; Peng TY; Chen J; Lu XM Dig Dis Sci; 2024 May; 69(5):1562-1570. PubMed ID: 38580886 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]